Pierre Fabre Laboratories dans l'actualité
Produits pharmaceutiques mondiaux, dermocosmétiques, leader français
Tamtam a trouvé 18 articles récents sur Pierre Fabre Laboratories.
- Ali Zeaiter Brings 20 Years of Oncology Experience to Pierre Fabre
- Pierre Fabre, Atara resubmit Ebvallo BLA after two FDA CRLs
- Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease to the FDA
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
- Laboratoires Pierre Fabre appoints Zombré CEO of U.S. Dermocosmetics operations in Secaucus
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO of U.S. Dermocosmetics Business, Signaling Next Phase of Growth
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO of U.S. Dermocosmetics Business, Signaling Next Phase of Growth
- Pierre Fabre appoints Venaïg Solinhac as CEO of Dermo-Cosmetics and Personal Care
- Pierre Fabre Invest increases its stake in MiYé to 38 %
- Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color
- Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metast
- Oxurion: Pierre Fabre Adopts Exagis Platform from its Subsidiary Axiodis
- Oxurion : Pierre Fabre adopte la plateforme Exagis de sa filiale Axiodis
- Major market validation: Pierre Fabre Laboratories uses Oxurion's Exagis Platform
- The Eau Thermale Avène brand is pushing Laboratoires Pierre Fabre to accelerate its production – Interview
- Pierre Fabre Laboratories Receives CHMP Positive Opinion For BRAFTOVI Combination In First Line BRAF Mutant Metastatic Colorectal Cancer
- Pierre Fabre plans to double production capacity at Avène plant in France
- Pierre Fabre : 50 millions d’euros pour doubler la production de l’usine d’Avène
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Pierre Fabre Laboratories ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires